盐酸苯达莫司汀-抗癌药物烷基化策略的复兴。

IF 1.8 4区医学 Q2 Medicine

Drugs of today Pub Date : 2009-06-01 DOI:10.1358/dot.2009.45.6.1376696

M Eichbaum, E Bischofs, K Nehls, A Schneeweiss, C Sohn

{"title":"盐酸苯达莫司汀-抗癌药物烷基化策略的复兴。","authors":"M Eichbaum, E Bischofs, K Nehls, A Schneeweiss, C Sohn","doi":"10.1358/dot.2009.45.6.1376696","DOIUrl":null,"url":null,"abstract":"Alkylating drugs represent one of the oldest classes of anticancer medicine used in a broad variety of clinical indications. Bendamustine hydrochloride (Ribomustine, Treanda) is a newer alkylating agent which has already been under intensive clinical investigation and has gained emerging interest due to its unique pharmacological properties, particularly in resistant or refractory diseases. This article provides basic information on the molecular mechanisms of action of bendamustine and its pharmacological characteristics and an overview on published clinical trials where bendamustine is analyzed as a single agent as well as in combination therapies for the treatment of solid tumors and hematologic malignancies.","PeriodicalId":11397,"journal":{"name":"Drugs of today","volume":" ","pages":"431-44"},"PeriodicalIF":1.8000,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.\",\"authors\":\"M Eichbaum, E Bischofs, K Nehls, A Schneeweiss, C Sohn\",\"doi\":\"10.1358/dot.2009.45.6.1376696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Alkylating drugs represent one of the oldest classes of anticancer medicine used in a broad variety of clinical indications. Bendamustine hydrochloride (Ribomustine, Treanda) is a newer alkylating agent which has already been under intensive clinical investigation and has gained emerging interest due to its unique pharmacological properties, particularly in resistant or refractory diseases. This article provides basic information on the molecular mechanisms of action of bendamustine and its pharmacological characteristics and an overview on published clinical trials where bendamustine is analyzed as a single agent as well as in combination therapies for the treatment of solid tumors and hematologic malignancies.\",\"PeriodicalId\":11397,\"journal\":{\"name\":\"Drugs of today\",\"volume\":\" \",\"pages\":\"431-44\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2009-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2009.45.6.1376696\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dot.2009.45.6.1376696","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

摘要

烷基化药物是最古老的一类抗癌药物，广泛应用于各种临床适应症。盐酸苯达莫司汀(Ribomustine, Treanda)是一种较新的烷基化剂，由于其独特的药理特性，特别是在耐药或难治性疾病中，已经得到了广泛的临床研究，并引起了人们的兴趣。本文提供了苯达莫司汀的分子作用机制及其药理特性的基本信息，并概述了苯达莫司汀作为单一药物和联合治疗实体瘤和血液系统恶性肿瘤的已发表的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.

Alkylating drugs represent one of the oldest classes of anticancer medicine used in a broad variety of clinical indications. Bendamustine hydrochloride (Ribomustine, Treanda) is a newer alkylating agent which has already been under intensive clinical investigation and has gained emerging interest due to its unique pharmacological properties, particularly in resistant or refractory diseases. This article provides basic information on the molecular mechanisms of action of bendamustine and its pharmacological characteristics and an overview on published clinical trials where bendamustine is analyzed as a single agent as well as in combination therapies for the treatment of solid tumors and hematologic malignancies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs of today 医学-药学

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： An international, peer-reviewed journal publishing monographs on new products entering the market and review articles. Since its inception in 1965, Drugs of Today has established a reputation for excellence in providing physicians and other key healthcare professionals with practical, up-to-date monographs on recently approved and launched drugs.